FORM PTO-1449 (REV. 7-85)

MENT OF COMMERCE U.S. DEPA TRADEMARK OFFICE PATENT 1

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

OCT 10 2001

ATTY. D QA211 **APPLICATION NO.** 09/848,694 **APPLICANT BANVILLE ET AL. FILING DATE** May 3, 2001

U.S. PATENT DOCUMENTS

| | | <u> </u> | | | | | |
|---------------------|-----|-----------------|----------|----------------------|-------|----------|-------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
| - su | AA | 5,866,318 | 2/2/99 | R. E. Rydel, et al | | | |
| Sie | AB | 5,453,443 | 9/26/95 | H. Perrier, et al | | | |
| SU | .AC | 5,478,857 | 12/26/95 | J. A. Clemens, et al | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | АН | | | | | | - |
| | Al | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRAN YES | SLATION NO |
|----------|-----|-----------------|---------|--------------------------------|-------------|----------|-------------|---------------|
| <u> </u> | AL/ | JP09268153A | 4/2/96 | JP-Derwent 97554679/51 English | | | | |
| Cle. | AM | WO 98/25893 | 6/18/98 | PCT Application | | | | |
| Su | AN | WO 98/08818 | 3/5/98 | PCT Application | | | | |
| SU | AO | WO 97/21676 | 6/19/97 | PCT Application | | | | |
| Su | AP | WO 99/15129 | 4/1/99 | PCT Application | | | | |

OTHER DOCUMENTS (Including Author Title Date De

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) | | | | | |
|---|----|---|--|--|--|
| Se | AQ | I. P. Street, et al, "Slow- and Tight-Binding Inhibitors of the 85-kDa Human Phospholipase A ₂ ," BIOCHEMISTRY, 32 , pp. 5935-5940, 1993 | | | |
| BL | | M. Abdullah, et al, "Synthesis and Preparation of an Affinity Chromatography Column for the Purification of Cytosolic Phospholipase A ₂ ," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 5 (5), pp. 519-522, 1995 | | | |
| çe | AS | D. L. Boger, et al, "Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 9, pp. 265-270, 1999 | | | |
| P. Norman, "Medicinal Chemistry in Eastern England-Ninth Symposium," IDRUGS, 1(1), pp. 49-54, AT 1998 | | | | | |
| EXAMINER | | S. Yuman DATE CONSIDERED 12/31/03 | | | |

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

__FOR PTO-1449 ATTY. DOCET NO. U.S. DEPAR INT OF COMMERCE RADEMARK OFFICE QA211 (RE. 7-85) PATENT AN INFORMATION DISCLOSURE CITATION APPLICATION 09/848,694 **APPLICANT** (Us s veral sheets if necessary) BANVILLE ET AL. **FILING DATE** May 3, 2001 THER DOCUMENTS (Including Author, Title, Date, P rtinent pages, Etc.) Clemens, et al, "Reactive Glia Express Cytosolic Phospholipase A2 After Transient Global brebrain Ischemia in the Rat," STROKE, 27(3), pp. 527-535, 1996 D. T. Stephenson, et al, "Cytosolic Phospholipase A2 (cPLA2) Immunoreactivity is Elevated in W Alzheimer's Disease Brain," NEUROBIOLOGY OF DISEASE, 3, pp. 51-63, 1996 ΑV Z. Huang, et al, "Methyl Arachidonyl Fluorophosphonate, a Potent Irreversible cPLA2 Inhibitor. Blocks the Mobilization of Arachidonic Acid in Human Platelets and Neutrophils," MEDIATORS OF W AW INFLAMMATION, 3, pp. 307-308, 1994 A. Gresham, et al, "Increased Synthesis of High-Molecular -Weight cPLA2 Mediates Early UV-Cl Induced PGE2 in Human Skin," AMERICAN JOURNAL OF PHYSIOLOGY, 270, pp. C1037-C1050, AX 1996 J. Balsinde, et al, "Distinct Roles in Signal Transduction for Each of the Phospholipase A2 Enzymes Present in P388D1 Macrophages," JOURNAL OF BIOLOGICAL CHEMISTRY, 271(12), AY pp. 6758-6765, 1996 ΑZ BA BB BC BD BE **BF** BG

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED

BH

-www.

EXAMINER